An interventional study of Tissue Procurement in Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center — 2 open to participants now, 4 under way, none of them phase 3. Osteosarcoma · Memorial Sloan Kettering Cancer Center.
Among the 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 3 that started in 1997, is the only one with no phase, and was the 15th registered.
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
Browse Osteosarcoma studies →2 of the 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 6–49
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 4+
By country, each count listing its studies:
Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 3 started in 1997.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 763 is above the median of 40 across 354 interventional studies indexed under Osteosarcoma.
Median enrollment 43 across the 10 interventional studies, 180 across the 2 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
3 of the studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03442465Memorial Sloan Kettering Cancer CenterAssessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas | 2027-02-14 |
| NCT02502786Memorial Sloan Kettering Cancer CenterHumanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma | 2027-07 |
| NCT00580385Memorial Sloan Kettering Cancer CenterChemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.
When tumor tissue known or presumed to be a primary or secondary bone cancer or solid tumor with known elevated intra-tumoral pressure such as retinoblastoma is being removed or has been removed for diagnostic or therapeutic reasons a small sample of it will be obtained for this study. The tumor samples will be used to study in vitro, determinants of chemotherapy resistance and oncogenesis. These determinants will be correlated with histologic response to preoperative chemotherapy and clinical outcome (event free survival). In addition, blood samples (20ml) may be obtained before or after the procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Tissue Procurement
MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
To test tumor samples obtained from patients with primary or secondary bone cancer for mechanisms of acquired and intrinsic resistance to methotrexate and to relate these findings to histologic response to preoperative chemotherapy and outcome.
Time frame: 2 years
To attempt to grow these tumor cells in short term culture to test the sensitivity of these cells to chemotherapeutic agents and to correlate cytotoxicity with biochemical and molecular studies.
Time frame: 2 years
The record gives a start of Aug 1997, a primary completion of Aug 2027 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →